Alnylam Pharmaceuticals Inc (ALNY)
How Alnylam Stock Weathers Market Shocks
Investing in equities involves accepting volatility as the cost of long-term compounding. In 15 significant systemic shocks during which Alnylam Pharmaceuticals (ALNY) was traded, the stock experienced an average drawdown of -25%.
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations
Alnylam Pharmaceuticals has declined nearly 40% from its all-time high, pressured by near-term TTR market dynamics and longer-term profitability concerns. The TTR business will likely remain "noisy" in the first half of 2026, but Amvuttra continues to gain share, and management guidance for 2026 was above expectations. Management alarmed the Street earlier this year with long-term spending guidance that was considerably higher than expected; management continues to prioritize R&D to realize the company's full long-term potential.
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down
Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2025 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.06 per share a year ago.
Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Alnylam (ALNY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy?
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Is Alnylam Pharmaceuticals a Millionaire Maker?
Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising.
